149 related articles for article (PubMed ID: 37083062)
1. Patients with deleterious germline mutations: A heterogeneous population for pancreatic cancer screening?
Roch AM; Kim RC; Nguyen TK; House MG; Zyromski NJ; Nakeeb A; Schmidt CM; Ceppa EP
J Surg Oncol; 2023 Aug; 128(2):289-294. PubMed ID: 37083062
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms.
Skaro M; Nanda N; Gauthier C; Felsenstein M; Jiang Z; Qiu M; Shindo K; Yu J; Hutchings D; Javed AA; Beckman R; He J; Wolfgang CL; Thompson E; Hruban RH; Klein AP; Goggins M; Wood LD; Roberts NJ
Gastroenterology; 2019 May; 156(6):1905-1913. PubMed ID: 30716324
[TBL] [Abstract][Full Text] [Related]
3. Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.
Abe T; Blackford AL; Tamura K; Ford M; McCormick P; Chuidian M; Almario JA; Borges M; Lennon AM; Shin EJ; Klein AP; Hruban RH; Canto MI; Goggins M
J Clin Oncol; 2019 May; 37(13):1070-1080. PubMed ID: 30883245
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Prevalence of Intraductal Papillary Mucinous Neoplasms in Individuals With BRCA1 and BRCA2 Pathogenic Variant.
Shah I; Silva-Santisteban A; Germansky KA; Wadhwa V; Tung N; Huang DC; Kandasamy C; Mlabasati J; Bilal M; Sawhney MS
J Clin Gastroenterol; 2023 Mar; 57(3):317-323. PubMed ID: 35220378
[TBL] [Abstract][Full Text] [Related]
5. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
[TBL] [Abstract][Full Text] [Related]
6. Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer?
Wang Y; Cuggia A; Chen YI; Parent J; Stanek A; Denroche RE; Zhang A; Grant RC; Domecq C; Golesworthy B; Shwaartz C; Borgida A; Holter S; Wilson JM; Chong G; O'Kane GM; Knox JJ; Fischer SE; Gallinger S; Gao ZH; Foulkes WD; Waschke KA; Zogopoulos G
J Natl Compr Canc Netw; 2022 Jun; 20(6):663-673.e12. PubMed ID: 35714671
[TBL] [Abstract][Full Text] [Related]
7. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.
Shindo K; Yu J; Suenaga M; Fesharakizadeh S; Cho C; Macgregor-Das A; Siddiqui A; Witmer PD; Tamura K; Song TJ; Navarro Almario JA; Brant A; Borges M; Ford M; Barkley T; He J; Weiss MJ; Wolfgang CL; Roberts NJ; Hruban RH; Klein AP; Goggins M
J Clin Oncol; 2017 Oct; 35(30):3382-3390. PubMed ID: 28767289
[TBL] [Abstract][Full Text] [Related]
8. Surveillance Outcome and Genetic Findings in Individuals at High Risk of Pancreatic Cancer.
Rosner G; Scapa E; Ziv T; Gluck N; Ben-Yehoyada M
Clin Transl Gastroenterol; 2024 Feb; 15(2):e00668. PubMed ID: 38147532
[TBL] [Abstract][Full Text] [Related]
9. Intraductal papillary mucinous neoplasm of the pancreas: associated cancers, family history, genetic predisposition?
Lubezky N; Ben-Haim M; Lahat G; Marmor S; Solar I; Brazowski E; Nackache R; Klausner JM
Surgery; 2012 Jan; 151(1):70-5. PubMed ID: 21975290
[TBL] [Abstract][Full Text] [Related]
10. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
Aslanian HR; Lee JH; Canto MI
Gastroenterology; 2020 Jul; 159(1):358-362. PubMed ID: 32416142
[TBL] [Abstract][Full Text] [Related]
11. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?
Roch AM; Schneider J; Carr RA; Lancaster WP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM; Ceppa EP
J Surg Oncol; 2019 May; 119(6):777-783. PubMed ID: 30636051
[TBL] [Abstract][Full Text] [Related]
12. EUS-based Pancreatic Cancer Surveillance in
Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
[TBL] [Abstract][Full Text] [Related]
14. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
[TBL] [Abstract][Full Text] [Related]
15. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer.
Majumder S; Philip NA; Singh Nagpal SJ; Takahashi N; Mara KC; Kendrick ML; Smyrk TC; Zhang L; Levy MJ; Gleeson FC; Petersen BT; Pearson RK; Topazian MD; Vege SS; Chari ST
Am J Gastroenterol; 2019 Mar; 114(3):524-529. PubMed ID: 30413822
[TBL] [Abstract][Full Text] [Related]
16. The Landmark Series: Intraductal Papillary Mucinous Neoplasms of the Pancreas-From Prevalence to Early Cancer Detection.
Pollini T; Wong P; Maker AV
Ann Surg Oncol; 2023 Mar; 30(3):1453-1462. PubMed ID: 36600097
[TBL] [Abstract][Full Text] [Related]
17. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.
Vasen H; Ibrahim I; Ponce CG; Slater EP; Matthäi E; Carrato A; Earl J; Robbers K; van Mil AM; Potjer T; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bergman W; Wasser M; Morreau H; Klöppel G; Schicker C; Steinkamp M; Figiel J; Esposito I; Mocci E; Vazquez-Sequeiros E; Sanjuanbenito A; Muñoz-Beltran M; Montans J; Langer P; Fendrich V; Bartsch DK
J Clin Oncol; 2016 Jun; 34(17):2010-9. PubMed ID: 27114589
[TBL] [Abstract][Full Text] [Related]
18. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance.
Okada T; Mizukami Y; Ono Y; Sato H; Hayashi A; Kawabata H; Koizumi K; Masuda S; Teshima S; Takahashi K; Katanuma A; Omori Y; Iwano H; Yamada M; Yokochi T; Asahara S; Kawakubo K; Kuwatani M; Sakamoto N; Enomoto K; Goto T; Sasajima J; Fujiya M; Ueda J; Matsumoto S; Taniue K; Sugitani A; Karasaki H; Okumura T
J Gastroenterol; 2020 Dec; 55(12):1183-1193. PubMed ID: 32939577
[TBL] [Abstract][Full Text] [Related]
19.
Collet L; Ghurburrun E; Meyers N; Assi M; Pirlot B; Leclercq IA; Couvelard A; Komuta M; Cros J; Demetter P; Lemaigre FP; Borbath I; Jacquemin P
Gut; 2020 Apr; 69(4):704-714. PubMed ID: 31154393
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic cancer screening in high-risk individuals with germline genetic mutations.
DaVee T; Coronel E; Papafragkakis C; Thaiudom S; Lanke G; Chakinala RC; Nogueras González GM; Bhutani MS; Ross WA; Weston BR; Lee JH
Gastrointest Endosc; 2018 Jun; 87(6):1443-1450. PubMed ID: 29309780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
